批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2020/05/28 |
SUPPL-18(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2020/05/28 |
SUPPL-13(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2012/11/30 |
SUPPL-11(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2011/01/27 |
SUPPL-8(补充) |
Approval |
Labeling |
|
|
|
2009/07/09 |
SUPPL-3(补充) |
Approval |
Labeling |
|
|
|
2006/09/18 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:FUROSEMIDE 剂型/给药途径:TABLET;ORAL 规格:20MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
016273 |
002 |
NDA |
LASIX |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
Yes |
No |
AB |
Approved Prior to Jan 1, 1982
|
VALIDUS PHARMS |
018487 |
001 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Discontinued |
No |
No |
AB |
Approved Prior to Jan 1, 1982
|
MYLAN |
018569 |
002 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
Approved Prior to Jan 1, 1982
|
EPIC PHARMA LLC |
018823 |
001 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
1983/11/10
|
HIKMA |
076796 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
2004/03/26
|
PRINSTON INC |
077293 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
2005/11/09
|
LEADING |
078010 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
2006/09/18
|
IPCA LABS LTD |
216629 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
20MG |
Prescription |
No |
No |
AB |
2022/10/17
|
GRAVITI PHARMS |
活性成分:FUROSEMIDE 剂型/给药途径:TABLET;ORAL 规格:40MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
016273 |
001 |
NDA |
LASIX |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
Yes |
No |
AB |
Approved Prior to Jan 1, 1982
|
VALIDUS PHARMS |
018487 |
002 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Discontinued |
No |
No |
AB |
Approved Prior to Jan 1, 1982
|
MYLAN |
018569 |
001 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
Approved Prior to Jan 1, 1982
|
EPIC PHARMA LLC |
018823 |
002 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
1983/11/10
|
HIKMA |
076796 |
002 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
2004/03/26
|
PRINSTON INC |
077293 |
002 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
2005/11/09
|
LEADING |
078010 |
002 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
2006/09/18
|
IPCA LABS LTD |
216629 |
002 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
40MG |
Prescription |
No |
No |
AB |
2022/10/17
|
GRAVITI PHARMS |
活性成分:FUROSEMIDE 剂型/给药途径:TABLET;ORAL 规格:80MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
016273 |
003 |
NDA |
LASIX |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
Yes |
Yes |
AB |
Approved Prior to Jan 1, 1982
|
VALIDUS PHARMS |
018569 |
005 |
NDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
1984/08/14
|
EPIC PHARMA LLC |
070086 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
1986/01/24
|
HIKMA |
070082 |
001 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Discontinued |
No |
No |
AB |
1986/10/29
|
MYLAN |
076796 |
003 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
2004/03/26
|
PRINSTON INC |
077293 |
003 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
2005/11/09
|
LEADING |
078010 |
003 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
2006/09/18
|
IPCA LABS LTD |
216629 |
003 |
ANDA |
FUROSEMIDE |
FUROSEMIDE |
TABLET;ORAL |
80MG |
Prescription |
No |
No |
AB |
2022/10/17
|
GRAVITI PHARMS |